120 related articles for article (PubMed ID: 19846945)
1. HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor.
Krawczyk N; Banys M; Neubauer H; Solomayer EF; Gall C; Hahn M; Becker S; Bachmann R; Wallwiener D; Fehm T
Anticancer Res; 2009 Oct; 29(10):4019-24. PubMed ID: 19846945
[TBL] [Abstract][Full Text] [Related]
2. The HER2 status of disseminated tumor cells in the bone marrow of early breast cancer patients is independent from primary tumor and predicts higher risk of relapse.
Hartkopf AD; Banys M; Meier-Stiegen F; Hahn M; Röhm C; Hoffmann J; Helms G; Taran FA; Wallwiener M; Walter C; Neubauer H; Wallwiener D; Fehm T
Breast Cancer Res Treat; 2013 Apr; 138(2):509-17. PubMed ID: 23494674
[TBL] [Abstract][Full Text] [Related]
3. Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients.
Solomayer EF; Becker S; Pergola-Becker G; Bachmann R; Krämer B; Vogel U; Neubauer H; Wallwiener D; Huober J; Fehm TN
Breast Cancer Res Treat; 2006 Jul; 98(2):179-84. PubMed ID: 16552629
[TBL] [Abstract][Full Text] [Related]
4. Trastuzumab clears HER2/neu-positive isolated tumor cells from bone marrow in primary breast cancer patients.
Rack B; Jückstock J; Günthner-Biller M; Andergassen U; Neugebauer J; Hepp P; Schoberth A; Mayr D; Zwingers T; Schindlbeck C; Friese K; Janni W
Arch Gynecol Obstet; 2012 Feb; 285(2):485-92. PubMed ID: 21717141
[TBL] [Abstract][Full Text] [Related]
5. Comparison of HER2 Expression in Primary Tumor and Disseminated Tumor Cells in the Bone Marrow of Breast Cancer Patients.
Rack B; Zombirt E; Trapp E; Jückstock J; Andergassen U; Neugebauer J; Kost B; Weissenbacher T; Jeschke U; Schindlbeck C; Janni W; Alunni-Fabbroni M
Oncology; 2016; 90(4):232-8. PubMed ID: 26937631
[TBL] [Abstract][Full Text] [Related]
6. Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial.
Witzel I; Loibl S; von Minckwitz G; Mundhenke C; Huober J; Hanusch C; Henschen S; Hauschild M; Lantzsch T; Tesch H; Latos K; Just M; Hilfrich J; Barinoff J; Eulenburg CZ; Roller M; Untch M; Müller V
Breast Cancer Res Treat; 2010 Sep; 123(2):437-45. PubMed ID: 20623180
[TBL] [Abstract][Full Text] [Related]
7. Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment.
Conte P; Guarneri V; Bengala C
Clin Breast Cancer; 2007 Dec; 7(11):841-9. PubMed ID: 18269773
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
Burris HA; Rugo HS; Vukelja SJ; Vogel CL; Borson RA; Limentani S; Tan-Chiu E; Krop IE; Michaelson RA; Girish S; Amler L; Zheng M; Chu YW; Klencke B; O'Shaughnessy JA
J Clin Oncol; 2011 Feb; 29(4):398-405. PubMed ID: 21172893
[TBL] [Abstract][Full Text] [Related]
9. Presence of apoptotic and nonapoptotic disseminated tumor cells reflects the response to neoadjuvant systemic therapy in breast cancer.
Fehm T; Becker S; Becker-Pergola G; Sotlar K; Gebauer G; Dürr-Störzer S; Neubauer H; Wallwiener D; Solomayer EF
Breast Cancer Res; 2006; 8(5):R60. PubMed ID: 17062129
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant trastuzumab for HER2-positive early breast cancer.
Palmieri FM; Myatt CV; Perez EA
Clin J Oncol Nurs; 2010 Jun; 14(3):326-36. PubMed ID: 20529794
[TBL] [Abstract][Full Text] [Related]
11. Implementation of trastuzumab in conjunction with adjuvant chemotherapy in the treatment of non-metastatic breast cancer in the Netherlands.
de Munck L; Schaapveld M; Siesling S; Wesseling J; Voogd AC; Tjan-Heijnen VC; Otter R; Willemse PH
Breast Cancer Res Treat; 2011 Aug; 129(1):229-33. PubMed ID: 21431871
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer.
Kiess AP; McArthur HL; Mahoney K; Patil S; Morris PG; Ho A; Hudis CA; McCormick B
Cancer; 2012 Apr; 118(8):1982-8. PubMed ID: 21887681
[TBL] [Abstract][Full Text] [Related]
13. Detection of cytokeratin-positive cells in the bone marrow of breast cancer patients undergoing adjuvant therapy.
Becker S; Becker-Pergola G; Wallwiener D; Solomayer EF; Fehm T
Breast Cancer Res Treat; 2006 May; 97(1):91-6. PubMed ID: 16319975
[TBL] [Abstract][Full Text] [Related]
14. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
Dressler LG; Berry DA; Broadwater G; Cowan D; Cox K; Griffin S; Miller A; Tse J; Novotny D; Persons DL; Barcos M; Henderson IC; Liu ET; Thor A; Budman D; Muss H; Norton L; Hayes DF
J Clin Oncol; 2005 Jul; 23(19):4287-97. PubMed ID: 15994142
[TBL] [Abstract][Full Text] [Related]
15. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2.
Gennari R; Menard S; Fagnoni F; Ponchio L; Scelsi M; Tagliabue E; Castiglioni F; Villani L; Magalotti C; Gibelli N; Oliviero B; Ballardini B; Da Prada G; Zambelli A; Costa A
Clin Cancer Res; 2004 Sep; 10(17):5650-5. PubMed ID: 15355889
[TBL] [Abstract][Full Text] [Related]
16. HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process.
Vincent-Salomon A; Jouve M; Genin P; Fréneaux P; Sigal-Zafrani B; Caly M; Beuzeboc P; Pouillart P; Sastre-Garau X
Cancer; 2002 Apr; 94(8):2169-73. PubMed ID: 12001113
[TBL] [Abstract][Full Text] [Related]
17. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
[TBL] [Abstract][Full Text] [Related]
18. Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy.
Ladoire S; Arnould L; Mignot G; Coudert B; Rébé C; Chalmin F; Vincent J; Bruchard M; Chauffert B; Martin F; Fumoleau P; Ghiringhelli F
Breast Cancer Res Treat; 2011 Jan; 125(1):65-72. PubMed ID: 20229175
[TBL] [Abstract][Full Text] [Related]
19. HER2 status and benefit from adjuvant trastuzumab in breast cancer.
Paik S; Kim C; Wolmark N
N Engl J Med; 2008 Mar; 358(13):1409-11. PubMed ID: 18367751
[No Abstract] [Full Text] [Related]
20. Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer.
McArthur HL; Mahoney KM; Morris PG; Patil S; Jacks LM; Howard J; Norton L; Hudis CA
Cancer; 2011 Dec; 117(24):5461-8. PubMed ID: 21681735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]